Gertjan H.J. Wagenvoort

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Mirjam J. Knol, Gertjan H.J. Wagenvoort, Elisabeth A. M. Sanders et al. · Emerging infectious diseases · 2015 · 75 citations · Full text

Vaccination, Vaccine Safety, Invasive Pneumococcal Disease +10

HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Colette Smit, Anders Boyd, Bart Rijnders et al. · The Lancet HIV · 2020 · 72 citations · Full text

Retrospective Cohort Study, Treatment And Prevention, Human Retrovirus +9

Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2–6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands

Gertjan H.J. Wagenvoort, Elisabeth A. M. Sanders, Bart J. M. Vlaminckx et al. · Vaccine · 2016 · 42 citations

Vaccination, Vaccine Safety, Vaccinology +8

Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia

Gertjan H.J. Wagenvoort, Elisabeth A. M. Sanders, Hester E. de Melker et al. · Vaccine · 2017 · 34 citations

Respiratory Infection, Infectious Respiratory Disease, Long-term Mortality +4

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015

Gertjan H.J. Wagenvoort, Elisabeth A. M. Sanders, Bart J. M. Vlaminckx et al. · Eurosurveillance · 2017 · 31 citations · Full text